ASND Stock Ascendis Pharma A/S
US · NasdaqGSLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Commercial launch, profitability, and limited competition support strong medium-term earnings visibility.
Future value: $307.17 (+31.08%) · 6-12 months · analyst consensus
Signal breakdown
- ▸RBC cites strong Yorvipath checks and a large underpenetrated indication.
- ▾Below 50-day MA (-3.65%)
- ▸~31% upside to price target
Is ASND a buy right now?
Trend: ASND is trading above the 50-day average (+0.32%), RSI 56 — neutral momentum, with a 3-month return of -3.97%.
Valuation & quality: Ascendis Pharma A/S trades on a trailing P/E of 18.8, forward P/E 27.3, price-to-book 9.98; fundamentals show net margin 70.8%, return on equity 118.8%, revenue growth 114.7% year on year.
Analyst consensus: 22 analysts have a mean 12-month price target of $304.01 (+24% vs the last close; range $261.22 – $342.50), consensus rating “strong buy”.
Our screen: BUY (score 3) — Commercial launch, profitability, and limited competition support strong medium-term earnings visibility.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -2.00% | +0.30% | -2.30% | +19.00% | -8.60% | +7.80% | -13.40% | +6.80% |
Fundamentals
Analyst price target
Technical signals
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Sector: Healthcare · Industry: Biotechnology · Denmark · 1,189 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.